1. Japan Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Lion Corporation

Lion Corporation

LIOPY
Lion CorporationUS flagOther OTC
16.40
USD
- -
- -
2.27BMarket Cap
Lion Corporation
LIOPY
(Other OTC)

Recent

price

16.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,457.35
2,439.36
2,494.88
2,624.05
2,740.4
2,790.99
2,735.22
2,358.74
2,404.48
2,390.94
2,444.73
2,519.42
2,738.19
2,832.33
2,981.01
3,052.12
2,918.74
Revenue per Share
44.81
30.37
31.53
45.44
54.95
78.7
110.27
143.73
176.21
141.45
205.5
163.44
154.09
102.84
153.02
199.48
144.72
Basic EPS, GAAP
150.9
22.49
73.58
60.74
-11.22
191.93
159.44
117.22
108.68
109.17
94.92
-162.52
132.16
38.59
178.02
- -
101.48
Free Cash Flow per Basic Share
20.18
20.02
22.03
19.94
20.05
19.6
19.97
29.97
39.97
39.97
43.97
47.98
48.43
51.93
52.62
- -
52.8
Dividend per Share
666.56
679.17
688.2
714.34
749.67
765.27
808.2
915.81
1,033.9
1,149.32
1,316.77
1,457.05
1,596.24
1,678.5
1,785.76
1,927.94
1,699.9
Book Value per Share
601.54
623.87
717.81
831.96
882.4
1,008.16
1,071.88
1,242.07
1,334.56
1,427.84
1,553.12
1,656.92
1,790.42
1,934.51
2,124.45
2,149.97
2,015.08
Tangible Book Value per Share
135
134
134
134
134
136
145
145
145
145
145
145
142
142
139
138
140
Basic Weighted Avg Shares
331,278
327,516
335,076
352,070
367,475
378,734
395,667
342,703
349,403
347,519
355,352
366,234
389,869
402,767
412,943
422,092
408,513
Sales/Revenue/Turnover
10.12
3.41
2.15
3.07
3.38
4.32
6.19
8.89
9.79
8.58
12.4
8.51
7.4
5.09
6.87
8.62
6.76
Operating Margin (%)
12,349
12,009
11,834
11,227
10,301
11,166
10,244
7,775
8,707
10,504
11,732
14,252
17,665
20,201
21,162
- -
20,526
Depreciation Expense
6,041
4,077
4,235
6,097
7,368
10,680
15,951
20,883
25,606
20,559
29,870
23,759
21,939
14,624
21,197
27,587
20,256
Net Income, GAAP
40.35
40.42
43.04
38.56
39.35
38.08
27.6
26.9
16.48
26.82
28.18
25.4
26.15
25.42
25.36
21.26
25.58
Effective Tax Rate (%)
1.82
1.24
1.26
1.73
2.01
2.82
4.03
6.09
7.33
5.92
8.41
6.49
5.63
3.63
5.13
6.54
4.96
Profit Margin (%)
28,729
32,621
34,905
16,494
30,638
45,583
62,029
70,120
86,192
86,779
78,791
92,932
96,117
88,941
109,046
117,768
87,059
Working Capital
27,504
25,087
22,670
204
16,878
4,508
1,690
1,569
1,202
6,399
5,324
5,480
28,990
28,150
27,637
26,189
27,795
LT Debt
105,760
105,251
114,160
124,230
127,432
142,727
157,877
188,792
204,271
221,201
244,856
265,014
279,167
298,133
315,693
348,418
304,325
Total Equity
13.38
4.62
2.88
4.34
4.71
6.3
10.73
12.12
13.98
9.78
12.62
8.61
7.23
4.75
6.17
7.75
6.2
Return on Invested Capital (%)
4.55
3.09
3.12
4.53
5.36
7.39
11.41
13.21
13.68
10.28
13.88
9.94
8.23
4.7
6.46
8.1
6.48
Return on Capital (%)
6.85
4.5
4.61
6.48
7.5
10.45
14.45
16.71
18.08
12.96
16.67
11.79
9.99
6.28
8.72
10.73
8.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
2,191
2,236
2,120
LT Borrowings
- -
- -
- -
LT Finance Leases
28,150
27,821
27,795
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
284
276
276
Market Capitalization
390,848
350,971
369,507

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
232,274
210,659
222,531
Cash, Cash Equivalents & STI
97,802
75,042
84,495
Accounts Receivable, Net
75,230
69,682
74,619
Inventories
56,090
61,935
59,591
Total Current Liabilities
143,333
127,424
135,472
Payables & Accruals
- -
- -
- -
ST Debt
2,191
2,236
2,120
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.4%
7.32%
10.37%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
14.21%
2.73%
30.15%
Sales/Revenue/Turnover
1.23%
3.51%
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
92,965
105,668
- -
- -
412,943
2025
- -
- -
- -
- -
422,092
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25.44
46.18
- -
- -
153.02
2025
- -
- -
- -
- -
199.48
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26.58
-0.09
- -
- -
52.62
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
KP Tissue Inc. (KPTSF)
Cupid Limited (CUPID.BO)
Church & Dwight Co., Inc. (CXU.DE)
Davi Luxury Brand Group, Inc. (MDAV)
Park Ha Biological Technology Co., Ltd. (PHH)
B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653" (PORF.AS)
Business
Lion Corporation (TSE: 4912; OTC: LIOPY) manufactures and sells a broad range of consumer products focused on daily hygiene and health needs, including toothpastes, toothbrushes, soaps, detergents, shampoos, rinses, cosmetics, fabric care items, dishwashing products, cooking-related goods, over-the-counter pharmaceuticals, and health supplements; it also produces industrial products such as chemical activators derived from oils and fats, and exports to overseas affiliates. The company operates through consumer products, industrial products, and overseas business segments, serving markets primarily in Japan, Thailand, Malaysia, Vietnam, China, Korea, Indonesia, Singapore, Hong Kong, and Taiwan with brands emphasizing oral care (where it leads Japan in toothpastes and toothbrushes), beauty care, fabric care, living care, and pharmaceuticals. Founded in 1891 and headquartered at 1-3-28 Kuramae, Taito-ku, Tokyo, Japan, Lion employs 7,654 people on a consolidated basis and reported net sales of ¥412.9 billion in fiscal year 2024. In recent developments, Lion signed a partnership agreement with Japan Activation Capital, Inc. in October 2024, under which JAC acquired common shares to support sustainable growth, profitability improvements in domestic consumer products, and overseas business expansion as part of the company's Vision2030 1st STAGE medium-term plan. Additionally, in April 2025, Lion announced the acquisition of the remaining 64% stake in equity-method affiliate Merap Lion Holding Corporation in Vietnam, converting it into a wholly owned subsidiary to enhance synergies in product development, production technology, and healthcare distribution networks covering hospitals, clinics, and pharmacies. These moves align with Lion's strategic shift to strengthen its overseas portfolio and integrate local strengths for greater market penetration in Southeast Asia.